Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Am J Psychiatry. 2012 Aug 1;169(8):805–812. doi: 10.1176/appi.ajp.2012.12010055

Figure 1.

Figure 1

Proportion of negative urine cannabinoid tests (intent-to-treat analysis including all randomized participants, with urine cannabinoid tests assumed to be positive for all missed visits; n=116); adjusted for years of cannabis use, baseline urine cannabinoid test results, and major depressive disorder. OR=2.4 (95% CI: 1.1-5.2), χ2=4.72, p=0.029

NAC=N-Acetylcysteine, BL=Baseline Visit, FU=Post-Treatment Follow-Up Visit